Physician profile
Denise Phan
NPI 1477656395
$4,978.37
in general payments reported to CMS, 2019-2025
37 companies · $802 in 2025
The $802 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $426 · 2021: $1,676 · 2022: $355 · 2023: $524 · 2024: $629 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,263.05 | 2021 | |
| Abbvie INC. | $922.38 | 2019-2025 | |
| Amgen INC. | $333.12 | 2019-2025 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $250.92 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $242.15 | 2019-2025 | |
| Novo Nordisk INC | $209.70 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Philips North America LLC | $197.64 | 2019-2023 | |
| Allergan, INC. | $187.37 | 2020 | |
| Glaxosmithkline, LLC. | $145.90 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.33 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.49 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $106.04 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $77.04 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $74.47 | 2025 | Gardasil 9, Capvaxive |
| Gilead Sciences, INC. | $68.85 | 2020-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.